Literature DB >> 25754200

Interleukin-6-driven inflammatory response induces retinal pathology in a model of ocular toxoplasmosis reactivation.

Élise Rochet1, Julie Brunet1, Marcela Sabou1, Luc Marcellin2, Tristan Bourcier3, Ermanno Candolfi1, Alexander W Pfaff4.   

Abstract

Ocular inflammation is one of the consequences of infection with the protozoan parasite Toxoplasma gondii. Even if lesions are self-healing in immunocompetent persons, they pose a lifetime risk of reactivation and are a serious threat to vision. As there are virtually no immunological data on reactivating ocular toxoplasmosis, we established a model of direct intravitreal injection of parasites in previously infected mice with a homologous type II strain. Two different mouse strains with variable ability to control retinal infection were studied in order to describe protective and deleterious reaction patterns. In Swiss-Webster mice, which are already relatively resistant to primary infection, no peak of parasite load was observed upon reinfection. In contrast, the susceptible inbred strain C57BL/6 showed high parasite loads after 7 days, as well as marked deterioration of retinal architecture. Both parameters were back to normal on day 21. C57BL/6 mice also reacted with a strong local production of inflammatory and Th1-type cytokines, like interleukin-6 (IL-6), IL-17A, and gamma interferon (IFN-γ), while Swiss-Webster mice showed only moderate expression of the Th2 cytokine IL-31. Interestingly, rapid intraocular production of anti-Toxoplasma antibodies was observed in Swiss-Webster but not in C57BL/6 mice. We then localized the cellular source of different immune mediators within the retina by immunofluorescence. Finally, neutralization experiments of IFN-γ or IL-6 demonstrated the respective protective and deleterious roles of these cytokines for parasite control and retinal integrity during reinfection. In conclusion, we developed and immunologically characterized a promising mouse model of reactivating ocular toxoplasmosis.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25754200      PMCID: PMC4399048          DOI: 10.1128/IAI.02985-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

Review 1.  Therapy for ocular toxoplasmosis--the future.

Authors:  Justus G Garweg; Miles R Stanford
Journal:  Ocul Immunol Inflamm       Date:  2013-04-25       Impact factor: 3.070

Review 2.  Therapeutic uses of anti-interleukin-6 receptor antibody.

Authors:  Sujin Kang; Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Int Immunol       Date:  2014-08-20       Impact factor: 4.823

3.  Experimental ocular toxoplasmosis in genetically susceptible and resistant mice.

Authors:  Fangli Lu; Shiguang Huang; Mark S Hu; Lloyd H Kasper
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Tissue cyst rupture in mice chronically infected with Toxoplasma gondii. An immunocytochemical and ultrastructural study.

Authors:  D J Ferguson; W M Hutchison; E Pettersen
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

5.  Ocular toxoplasmosis: clinical features and prognosis of 154 patients.

Authors:  Lotje E H Bosch-Driessen; Tos T J M Berendschot; Jenny V Ongkosuwito; Aniki Rothova
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

6.  Host Cell Preference of Toxoplasma gondii Cysts in Murine Brain: A Confocal Study.

Authors:  T C Melzer; H J Cranston; L M Weiss; S K Halonen
Journal:  J Neuroparasitology       Date:  2010

7.  Quality of life assessment in ocular toxoplasmosis in a Colombian population.

Authors:  Alejandra de-la-Torre; Gilberto González-López; Johanna Milena Montoya-Gutiérrez; Viviana Marín-Arango; Jorge Enrique Gómez-Marín
Journal:  Ocul Immunol Inflamm       Date:  2011-08       Impact factor: 3.070

8.  Murine neonatal infection provides an efficient model for congenital ocular toxoplasmosis.

Authors:  Ibtissem Lahmar; Marie Guinard; Arnaud Sauer; Luc Marcellin; Tamer Abdelrahman; Michel Roux; Marc Mousli; Adnan Moussa; Hamouda Babba; Alexander W Pfaff; Ermanno Candolfi
Journal:  Exp Parasitol       Date:  2009-09-13       Impact factor: 2.011

9.  CD4 T-cell suppression by cells from Toxoplasma gondii-infected retinas is mediated by surface protein PD-L1.

Authors:  Elizabeth Charles; Sunil Joshi; John D Ash; Barbara A Fox; A Darise Farris; David J Bzik; Mark L Lang; Ira J Blader
Journal:  Infect Immun       Date:  2010-05-24       Impact factor: 3.441

10.  Severe South American ocular toxoplasmosis is associated with decreased Ifn-γ/Il-17a and increased Il-6/Il-13 intraocular levels.

Authors:  Alejandra de-la-Torre; Arnaud Sauer; Alexander W Pfaff; Tristan Bourcier; Julie Brunet; Claude Speeg-Schatz; Laurent Ballonzoli; Odile Villard; Daniel Ajzenberg; Natarajan Sundar; Michael E Grigg; Jorge E Gomez-Marin; Ermanno Candolfi
Journal:  PLoS Negl Trop Dis       Date:  2013-11-21
View more
  13 in total

1.  CCR5 Is Involved in Interruption of Pregnancy in Mice Infected with Toxoplasma gondii during Early Pregnancy.

Authors:  Maki Nishimura; Kousuke Umeda; Masayuki Suwa; Hidefumi Furuoka; Yoshifumi Nishikawa
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

Review 2.  The molecular biology and immune control of chronic Toxoplasma gondii infection.

Authors:  Xiao-Yu Zhao; Sarah E Ewald
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

3.  The broad-spectrum chemokine inhibitor NR58-3.14.3 modulates macrophage-mediated inflammation in the diseased retina.

Authors:  Nilisha Fernando; Riccardo Natoli; Krisztina Valter; Jan Provis; Matt Rutar
Journal:  J Neuroinflammation       Date:  2016-02-24       Impact factor: 8.322

4.  Experimental Models of Ocular Infection with Toxoplasma Gondii.

Authors:  Agata Dukaczewska; Roberto Tedesco; Oliver Liesenfeld
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-12-04

5.  Rapid monocyte infiltration following retinal detachment is dependent on non-canonical IL6 signaling through gp130.

Authors:  Xinlei Wang; Eric B Miller; Mayank Goswami; Pengfei Zhang; Kaitryn E Ronning; Sarah J Karlen; Robert J Zawadzki; Edward N Pugh; Marie E Burns
Journal:  J Neuroinflammation       Date:  2017-06-23       Impact factor: 8.322

6.  Immune Mediator Profile in Aqueous Humor Differs in Patients with Primary Acquired Ocular Toxoplasmosis and Recurrent Acute Ocular Toxoplasmosis.

Authors:  Claudia Thieme; Stephan Schlickeiser; Sylvia Metzner; Claudia Dames; Uwe Pleyer
Journal:  Mediators Inflamm       Date:  2019-02-17       Impact factor: 4.711

7.  Type I ROP16 regulates retinal inflammatory responses during ocular toxoplasmosis.

Authors:  Elise Rochet; Nicolas Argy; Valentin Greigert; Julie Brunet; Marcela Sabou; Luc Marcellin; Alejandra de-la-Torre; Arnaud Sauer; Ermanno Candolfi; Alexander W Pfaff
Journal:  PLoS One       Date:  2019-03-22       Impact factor: 3.240

8.  Toxoplasma gondii seroprevalence varies by cat breed.

Authors:  Kärt Must; Marjo K Hytönen; Toomas Orro; Hannes Lohi; Pikka Jokelainen
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

9.  Extracellular Vesicles Secreted by Neospora caninum Are Recognized by Toll-Like Receptor 2 and Modulate Host Cell Innate Immunity Through the MAPK Signaling Pathway.

Authors:  Shan Li; Pengtao Gong; Lixin Tai; Xin Li; Xiaocen Wang; Chunyan Zhao; Xu Zhang; Zhengtao Yang; Ju Yang; Jianhua Li; Xichen Zhang
Journal:  Front Immunol       Date:  2018-07-24       Impact factor: 7.561

10.  Differences in Ocular Complications Between Candida albicans and Non-albicans Candida Infection Analyzed by Epidemiology and a Mouse Ocular Candidiasis Model.

Authors:  Masahiro Abe; Yuki Kinjo; Keigo Ueno; Shogo Takatsuka; Shigeki Nakamura; Sho Ogura; Muneyoshi Kimura; Hideki Araoka; Sota Sadamoto; Minoru Shinozaki; Kazutoshi Shibuya; Akiko Yoneyama; Mitsuo Kaku; Yoshitsugu Miyazaki
Journal:  Front Microbiol       Date:  2018-10-17       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.